Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DISULFIRAM vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Alcohol dependence (FDA-approved),Off-label: Cocaine dependence (limited evidence)
Management of mild to moderate pain,Reduction of fever
250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Approximately 7–10 hours for parent drug; however, the disulfiram-ethanol reaction can persist up to 14 days due to irreversible inhibition of aldehyde dehydrogenase (ALDH) and slow regeneration of the enzyme. The active metabolite, diethyldithiocarbamate, has a half-life of about 15 hours.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Disulfiram is rapidly metabolized in the liver to diethyldithiocarbamate, which is further metabolized; it is primarily excreted in urine and feces.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Primarily renal as metabolites; approximately 80% of a dose is excreted in urine as glucuronide conjugates and other metabolites, with less than 20% excreted in feces via bile. A small amount is eliminated unchanged in urine.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Approximately 96% bound primarily to albumin and also to lipoproteins.
10-25% bound to albumin at therapeutic concentrations.
Approximately 2–4 L/kg, indicating extensive tissue distribution and accumulation, particularly in adipose tissue due to lipophilicity.
0.8-1.0 L/kg; suggests distribution into total body water.
Rapidly and almost completely absorbed after oral administration; absolute bioavailability is approximately 70–90% due to first-pass metabolism in the liver. No parenteral forms are approved; only oral route (tablets) is used clinically.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dose adjustment required for renal impairment; no specific GFR-based guidelines exist; use with caution in severe renal impairment.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), no specific dose adjustment, but monitor liver function. Not recommended in active liver disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not recommended for use in patients under 18 years due to lack of established safety and efficacy.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at lower dose (125 mg/day) due to age-related decreased function; monitor closely for adverse effects.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Disulfiram should never be administered to a patient who is in a state of alcohol intoxication or without the patient's full knowledge and consent. The patient must be fully informed of the disulfiram-alcohol reaction.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Hepatotoxicity including hepatitis and hepatic failure; peripheral neuropathy; optic neuritis; psychotic reactions; hypersensitivity; risk of severe disulfiram-alcohol reaction if alcohol is consumed.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Concurrent use of alcohol or alcohol-containing preparations; metronidazole; paraldehyde; severe myocardial disease; coronary occlusion; psychosis; severe hepatic impairment; hypersensitivity to disulfiram or other thiuram derivatives.
Hypersensitivity to acetaminophen or any component of the formulation
Avoid foods and products containing alcohol: sauces (e.g., wine sauces, beer batter), vinegar (especially red/white wine vinegar), marinades, ripe fruits (fermentation can produce trace alcohol), some desserts (e.g., tiramisu, fruitcakes), alcohol-infused chocolates, non-alcoholic beer/wine (may contain up to 0.5% alcohol). Also avoid mouthwashes, breath sprays, and hand sanitizers with ethanol. Some medications like paraldehyde, chloral hydrate, and metronidazole may cross-react. Even alcohol in cooking may not fully evaporate and can trigger a reaction.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: No specific malformation patterns reported; however, theoretical risk of disulfiram-ethanol reaction causing fetal hypoxia due to maternal acetaldehyde accumulation. Use only if essential and with strict alcohol avoidance.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Excreted into breast milk in small amounts (M/P ratio not established). No adverse effects reported in nursing infants. However, theoretical risk of disulfiram-ethanol reaction if mother consumes alcohol. Recommend caution and discuss with healthcare provider; generally consider compatible with breastfeeding if mother abstains from alcohol.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No specific dose adjustment recommended in pregnancy. Pharmacokinetic studies in pregnancy not available. Use lowest effective dose (typically 250 mg/day) to minimize risks. Avoid higher loading doses. Discontinue if signs of hepatotoxicity occur.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to severe nausea, vomiting, hypotension, and flushing. Avoid use in patients with severe heart disease, psychosis, or cirrhosis. Monitor LFTs and CBC at baseline and periodically. Disulfiram may also inhibit CYP450 enzymes (CYP2E1, CYP1A2, CYP3A4), potentiating warfarin, phenytoin, and theophylline. Onset of aversion therapy requires 12-48 hours after the last alcohol dose; maintain alcohol-free period of 24 hours before starting. Duration of action persists up to 14 days after discontinuation. Inadvertent alcohol exposure in topical products (mouthwash, colognes) can trigger reactions.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Avoid all forms of alcohol, including beverages, mouthwash, cough syrup, cooking wine, vinegar, aftershave, and hand sanitizers.,Reaction to alcohol includes severe flushing, nausea, vomiting, chest pain, difficulty breathing, and blurred vision; seek emergency care if symptoms occur.,The disulfiram-alcohol reaction can be fatal even with small amounts of alcohol.,Inform all healthcare providers (including dentists) that you are taking disulfiram.,Reactions may occur up to 14 days after stopping the medication.,Do not take disulfiram if you have recently consumed alcohol; wait at least 12 hours after the last drink.,Carry a medical alert card or wear a bracelet stating you are on disulfiram.,Report any signs of liver toxicity: yellowing of eyes/skin, dark urine, severe fatigue.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Rifapentine, a potent inducer of cytochrome P450 enzymes, significantly increases the metabolism of disulfiram by inducing hepatic CYP3A4 and other metabolic pathways. This induction reduces disulfiram plasma concentrations, potentially diminishing its therapeutic efficacy in maintaining alcohol aversion. The interaction may lead to an increased risk of alcohol consumption relapse and associated clinical consequences."
"Disulfiram inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation, but also inhibits CYP3A4 and other CYP enzymes. Palbociclib is primarily metabolized by CYP3A4 and is a substrate of this enzyme. Coadministration with disulfiram can significantly increase palbociclib serum concentrations, raising the risk of dose-dependent toxicities such as neutropenia, infections, and fatigue."
"Disulfiram irreversibly inhibits aldehyde dehydrogenase and also suppresses the activity of cytochrome P450 (CYP) 2D6 and other CYP enzymes, thereby reducing the hepatic metabolism of venlafaxine. This can lead to increased plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine, elevating the risk of dose-dependent adverse effects such as hypertension, nausea, dizziness, and serotonin syndrome. Additionally, disulfiram's own metabolism may be affected, potentially increasing the severity of disulfiram-ethanol reactions."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DISULFIRAM vs INJECTAPAP, answered by our medical review team.
DISULFIRAM is a Aldehyde Dehydrogenase Inhibitor that works by Disulfiram irreversibly inhibits aldehyde dehydrogenase, causing accumulation of acetaldehyde after alcohol ingestion, leading to aversive effects such as flushing, nausea, and hypotension.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DISULFIRAM and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DISULFIRAM is: 250 mg orally once daily, increased to 500 mg orally once daily if needed; maintenance dose typically 250 mg per day (range 125-500 mg).. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DISULFIRAM and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DISULFIRAM is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show embryotoxic effects at high doses. Avoid unless benefit outweighs risk. Second and third trimesters: . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.